Lamicone ZN Tablet contains a combination of Lamivudine 150mg, Zidovudine 300mg, and Nevirapine 200mg, a highly effective antiretroviral therapy (ART) formulation indicated for the management of HIV infection. It helps suppress viral replication, control viral load, and support immune system function in HIV-positive patients.
The combination works synergistically: Lamivudine and Zidovudine inhibit reverse transcriptase, while Nevirapine blocks viral replication at a different site. Together, they provide comprehensive viral suppression, improving immune function and long-term health outcomes.
For distributors and healthcare suppliers, Lamicone ZN Tablet is a high-demand ART product, widely prescribed in HIV clinics, hospitals, and infectious disease centers. The increasing prevalence of HIV and need for effective combination therapy ensure continuous demand throughout urban and rural healthcare networks.
Adding Lamicone ZN Tablet to your antiretroviral and viral suppression segment provides strong opportunities in pharmacies, hospital supply chains, HIV care centers, export markets, and third-party manufacturing. Its clinically proven efficacy, patient adherence profile, and broad therapeutic application make it a valuable addition for pharmaceutical distribution.